Knowledge of the Molecular Signaling Pathways Improves the Chances of Treatment of Gastrointestinal Stromal Tumors

Crossmark: check for updates

Authors

  • Joana Espiga de Macedo Oncologist, Department of Medical Oncology, Centro Hospitalar de Entre o Douro e Vouga, Portugal

DOI:

https://doi.org/10.17140/CSMMOJ-2-109

Abstract

Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal (nonepithelial) tumors of the gastrointestinal tract. A better molecular understanding of this entity, as Christopher L. Cordless in Modern Pathology in 20141 demonstrated, GISTs mainly a result from two-level changes in two Oncogenes: KIT oncogene (75%) and PDGFRA oncogene (α receptor platelet-derived growth factor) which occurs in about 10% of cases; the remaining 15% are designated wild type tumors.

References

Corless CL. Gastrointestinal stromal tumors: what do we know now? Modern Pathology. 2014; 27: S1-S16. doi: 10.1038/ modpathol.2013.173

Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925-932.

Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mu-tations of c-kit in human gastrointestinal stromal tumors. Sci-ence. 1998; 279: 577-580. doi: 10.1126/science.279.5350.577

Knowlton CA, Brady LW, Heintzelman RC. Radiotherapy in the treatment of gastrointestinal stromal tumor. Rare Tumors. Cancer Stud Mol Med Open J 2011; 3: e35. doi: 10.4081/rt.2011.e35

DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinibmesylate after resection of localised, primary gastroin-testinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1097-1104. doi: 10.1016/ S0140-6736(09)60500-6

Joensuu H, Eriksson M, Sundby Hall K, et al. Twelve vs. 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SS-GXVIII/AIO). JAMA. 2012; 307: 1265-1272.

Hislop J, Mowatt G, Sharma P, et al. Systematic review of es-calated imatinib doses compared with sunitinib or best support-ive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. J Gastrointest Cancer. 2012; 43: 168-176. doi: 10.1007/s12029-011-9325-6

Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a ran-domised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013; 14: 1175-1182. doi: 10.1016/S1470-2045(13)70453-4

Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-1338.

Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safe-ty of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lan-cet. 2013; 381: 295-302. doi: 10.1016/S0140-6736(12)61857-1

Rutkowski P, Gronchi A. Efficacy and Economic Value of Adjuvant Imatinib for Gastrointestinal Stromal Tumors. The Oncologist. 2013; 18: 689-696. doi: 10.1634/theoncolo-gist.2012-0474

Cesne AL, Blay JY, Reichardt P, Joensuu H. Optimizing Ty-rosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tu-mors: Exploring the Benefits of Continuous Kinase Suppression. The Oncologist. 2013; 18: 1192-1199. doi: 10.1634/theoncolo-gist.2012-0361

Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant ima-tinib therapy. Journal of Medical Economics. 2014; 241-248. doi: 10.3111/13696998.2014.991787

Downloads

Published

2015-08-05

How to Cite

Joana Espiga de Macedo. (2015). Knowledge of the Molecular Signaling Pathways Improves the Chances of Treatment of Gastrointestinal Stromal Tumors. Cancer Studies and Molecular Medicine , 2(1), 69–71. https://doi.org/10.17140/CSMMOJ-2-109

Issue

Vol. 2 No. 1 (2015): Volume 2 Issue 1 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.